Biggest News Aggregation in the World
📰 Arnaud Delepine News

Page 3 - Arnaud Delepine News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Arnaud Delepine. Real-time updates on events, politics, business and more.

Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi Seite 1

16.12.2021 -     Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of SanofiPARIS – December 16, 2021 - On December 15, 2021, the Board of Directors appointed Gilles Schnepp, an independent director of Sanofi, as Chairman ... Seite 1
United States France General Eva Schaefer Jansen Arnaud Delepine Sandrine Guendoul Felix Lauscher

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaki

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session  Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and seco...
United States France General Eva Schaefer Jansen Arnaud Delepine Felix Lauscher Amys Paller

Sanofi - Aventis Groupe: Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking sessions

Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking
France General United States Eva Schaefer Jansen Arnaud Delepine Felix Lauscher Nathalie Pham

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Sanofi - Aventis Groupe: Positive Phase 3 Dupixent (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session

Positive Phase 3 Dupixent (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session Dupixent significantly improved skin
United States France General Eva Schaefer Jansen Arnaud Delepine Felix Lauscher Amys Paller

Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

Investegate announcements from Sanofi - Aventis Groupe, New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
United States France General Vanderbilt University Eva Schaefer Jansen Arnaud Delepine Felix Lauscher

Sanofi - Aventis Groupe: New England Journal of Medicine publishes positive Phase 3 Dupixent (dupilumab) results in children with moderate-to-severe asthma

New England Journal of Medicine publishes positive Phase 3 Dupixent (dupilumab) results in children with moderate-to-severe asthma Dupixent significantly reduced severe asthma attacks and improved
United States France General Vanderbilt University Eva Schaefer Jansen Arnaud Delepine Felix Lauscher

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science